MicroRNAs as prognostic markers in ovarian cancer

Llauradó, Marta; Majem, Blanca; Altadill, Tatiana; Lanau, Lucia; Castellví, Josep; Sánchez-Iglesias, José Luís; Cabrera, Sílvia; Torre, Javier de la; Díaz-Feijoó, Berta; Pérez-Benavente, Asunción; Colás, Eva; Oliván, Mireia; Doll, Andreas; Alameda, Francesc; Matías‐Guiu, Xavier; Moreno‐Bueno, Gema; Carey, Mark; Campo, J. M. Del; Gil‐Moreno, Antonio; Reventós, Jaume; Rigau, Marina

doi:10.1016/j.mce.2014.03.006

Cited by 32 publications

(31 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is evident that miRNAs could control also the expression of genes that are involved in drug response and therefore they could also play a role in Pharmacogenomics. Several studies have described the role of miRNA in drug response especially in cancer treatments in terms of drug resistance [18][19][20] but also in inflammatory bowel disease treatment [21]. Few studies have also described that polymorphisms in miRNA target regions could affect the expression of the genes and therefore the response to the treatment.…”

Section: Discussionmentioning

confidence: 99%

“…MicroRNAs (miRNAs or miRs) are a recently discovered class of small (19)(20)(21)(22)(23)(24) nucleotides) endogenous non-coding oligonucleotides that regulate gene expression at the post-transcriptional level [1][2][3]. They play a crucial role in regulation of physiological and pathological processes and some miRNAs have been described as associated with distinct clinical characteristics, such as diagnosis or disease activity [4][5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes

Ciccacci

Rufini

Politi

et al. 2015

Thrombosis Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes

Ciccacci

Rufini

Politi

et al. 2015

Thrombosis Research

View full text Add to dashboard Cite

“…Samples were tested for 16 HPV subtypes (HPV 6,11,16,18,31,33,35,39,45,51,52,56,58,59,66, and 68) using multiplexbased fluorescence PCR (F-HPV typing™, Genomed Diagnostics AG, Paisley, United Kingdom). Samples were tested for 16 HPV subtypes (HPV 6,11,16,18,31,33,35,39,45,51,52,56,58,59,66, and 68) using multiplexbased fluorescence PCR (F-HPV typing™, Genomed Diagnostics AG, Paisley, United Kingdom).…”

Section: Hpv16mentioning

confidence: 99%

“…They take part in posttranscriptional gene silencing by binding complementary sequences of target messenger RNAs, resulting in inhibition of translation or degradation of the targeted messenger RNA. [10][11][12] The number of miRNA expression profiling studies and research about miRNA-based biomarkers in OSCC has recently increased considerably, particularly in the Asian region, whereas research about miRNA-based biomarkers has only scarcely been investigated in Europe. This has an impact on tumor growth, invasion, apoptosis, and immune response.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA expression patterns in oral squamous cell carcinoma: hsa‐mir‐99b‐3p and hsa‐mir‐100‐5p as novel prognostic markers for oral cancer

et al. 2019

View full text Add to dashboard Cite

Background MicroRNAs (miRNA) recently evolved as potential cancer biomarkers. Therefore, the aim of the present study was to evaluate the prognostic impact of eight miRNAs connected to oral squamous cell carcinoma (OSCC). Method Expression levels of hsa‐mir‐21‐5p, hsa‐mir‐29b‐3p, hsa‐mir‐31‐5p, hsa‐mir‐99a‐5p, hsa‐mir‐99b‐3p, hsa‐mir‐100‐5p, hsa‐mir‐143‐3p and hsa‐mir‐155‐5p were analyzed in tumor tissue (n = 36) and healthy oral mucosal tissue (n = 17) and correlated with clinical variables. Results of the study cohort were validated in an OSCC cohort of The Cancer Genome Atlas. Results Increased hsa‐mir‐99b‐3p expression level showed a tendency toward advanced tumor stages, and high levels of hsa‐mir‐100‐5p expression were associated with extracapsular extension. While a high expression level of hsa‐mir‐99b‐3p was associated with better survival, a high expression level of hsa‐mir‐100‐5p was correlated with a poorer survival in the study cohort. Conclusion Our results indicate that hsa‐mir‐99b‐3p and hsa‐mir‐100‐5p may serve as novel prognostic biomarkers in OSCC.

show abstract

“…Accumulating studies have confirmed that miRNAs play important roles in the development and progression of various human cancers,8–13 including OS, and miRNAs have been regarded as promising biomarkers and therapeutic targets of OC 9,14…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-216a promotes the metastasis and epithelial–mesenchymal transition of ovarian cancer by suppressing the PTEN/AKT pathway

Liu

Pan

Han

et al. 2017

OTT

View full text Add to dashboard Cite

MicroRNAs, a group of posttranscriptional regulators of numerous genes, are active participators during the development and progression of ovarian cancer (OC). This study confirmed for the first time that miR-216a was gradually increased in normal, benign, borderline, and OC tissues and that its expression was significantly upregulated in all OC cell lines. Analysis of its clinical association demonstrated that elevated expression of miR-216a was associated with lymph node metastasis and advanced FIGO stage and was correlated with the poor survival of OC patients. Functional experiments showed that miR-216a overexpression potentiated the migration and invasion of CAOV3 cells while miR-216a inhibition reduced the migration and invasion of SKOV-3 cells. Both gain and lose of function assay showed that miR-216a promoted epithelial–mesenchymal transition (EMT) of OC cells. Mechanistically, phosphatase and tensin homolog (PTEN) was confirmed as a direct downstream target of miR-216a in OC cells. Alerting miR-216a expression in OC cells modulated the activity of PTEN/AKT pathway in OC cells. Furthermore, this study confirmed that miR-216a exerted its promoting effects on the metastatic behaviors and EMT of OC cells by inhibiting PTEN/AKT pathway. Taken together, this study demonstrates that miR-216a exerts a promoting role in the metastasis of OC and can serve as a promising biomarker and an attractive therapeutic target of OC.

show abstract

MicroRNAs as prognostic markers in ovarian cancer

Cited by 32 publications

References 82 publications

Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes

Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes

MicroRNA expression patterns in oral squamous cell carcinoma: hsa‐mir‐99b‐3p and hsa‐mir‐100‐5p as novel prognostic markers for oral cancer

MicroRNA-216a promotes the metastasis and epithelial–mesenchymal transition of ovarian cancer by suppressing the PTEN/AKT pathway

Contact Info

Product

Resources

About

MicroRNAs as prognostic markers in ovarian cancer

Cited by 32 publications

References 82 publications

Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes

Could MicroRNA polymorphisms influence warfarin dosing? A pharmacogenetics study on mir133 genes

MicroRNA expression patterns in oral squamous cell carcinoma: hsa‐mir‐99b‐3p and hsa‐mir‐100‐5p as novel prognostic markers for oral cancer

MicroRNA-216a promotes the metastasis and epithelial&ndash;mesenchymal transition of ovarian cancer by suppressing the PTEN/AKT pathway

Contact Info

Product

Resources

About

MicroRNA-216a promotes the metastasis and epithelial–mesenchymal transition of ovarian cancer by suppressing the PTEN/AKT pathway